Clinical Trials
Novel Approach
Imetelstat inhibits the activity of the enzyme telomerase, a key target for anti-cancer therapeutics.
Learn more
Imetelstat in Patients With Essential Thrombocythemia
Helpful Information
- Hematologic response is a decrease or normalization of platelets after treatment.
- Molecular response rate is the percentage of patients who have a reduction in the percentage of mutant JAK2 or MPL alleles detected in their blood cells.
A Phase 2 Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy
Geron is enrolling patients in a clinical trial to evaluate the potential activity of our product candidate, imetelstat, in patients with essential thrombocythemia (ET). This study is open to patients who have failed or are intolerant to at least one prior therapy, or who refuse standard therapy.
In the Phase 2 clinical trial, our clinical researchers and investigators are studying how imetelstat may affect the hematologic response in patients who have not responded to, or have not been able to tolerate, at least one other treatment, or who have refused standard therapy.
The study will also measure the length of time patients respond to the treatment from the first dose through to 12 months after the end of the study. In patients who have a mutation in the JAK2 or MPL genes, we will collect data to evaluate the rate of molecular response.
Imetelstat is an investigational treatment for cancer in development by Geron and has not been approved by the FDA or any other regulatory agency.
About Imetelstat
Imetelstat inhibits the activity of telomerase, which is an enzyme present in most types of cancer that enables tumor cells to replicate indefinitely. One of Geron's potential anti-cancer strategies is to stop or slow down the growth and spread of tumors by inhibiting telomerase activity. Learn more
Cancer Definitions
To learn more about the terms and definitions used in cancer clinical studies you may find the National Cancer Institute Dictionary of Cancer Terms a useful resource.
Para obtener más información acerca de los términos y las definiciones utilizadas en los estudios clínicos sobre el cáncer es posible que el Instituto Nacional del Cáncer Diccionario de cáncer en un recurso útil.
How to Participate
To learn more about how to participate in this clinical trial, please visit ClinicalTrials.gov for the full trial summary and enrollment criteria.
Additionally, patients or their physicians may directly contact the nearest trial center for more information about how to participate. The study is currently being conducted in multiple trial centers across the United States, Germany and Switzerland.
Novel Approach
Imetelstat inhibits the activity of the enzyme telomerase, a key target for anti-cancer therapeutics.
Learn more
